Clinical Trial Update: Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SHR6390 with Pyrotinib for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• SHR6390 (SHR6390)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN